U.S. COMPANY FILING
VERTEX PHARMACEUTICALS INC / MA — Form 10-Q filed 2026-08-04
Filing text preview
Vertex's Q2 2026 total revenues rose to $3.33B, up 12.5% YoY, driven by CF therapies and new products. Net income was $1.10B, EPS $4.31. Announced acquisition of Crinetics for ~$10B and a $4.5B term loan. ALYFTREK and CASGEVY showed strong growth.
This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.
Open filing record